Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles
- PMID: 22508377
- PMCID: PMC4846333
- DOI: 10.3791/3171
Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles
Abstract
As with standard plasmid vectors, it is possible to transfect lentivectors in plasmid form into cells with low-to-medium efficiency to obtain transient expression of effectors. Packaging lentiviral expression constructs into pseudoviral particles, however, enables up to 100% transduction, even with difficult-to-transfect cells, such as primary, stem, and differentiated cells. Moreover, the lentiviral delivery does not produce the specific cellular responses typically associated with chemical transfections, such as cell death resulting from toxicity of the transfection reagent. When transduced into target cells, the lentiviral construct integrates into genomic DNA and provides stable expression of the small hairpin RNA (shRNA), cDNA, microRNA or reporter gene. Target cells stably expressing the effector molecule can be isolated using a selectable marker contained in the expression vector construct such as puromycin or GFP. After pseudoviral particles infect target cells, they cannot replicate within target cells because the viral structural genes are absent and the long terminal repeats (LTRs) are designed to be self-inactivating upon transduction. There are three main components necessary for efficient lentiviral packaging. 1. The lentiviral expression vector that contains some of the genetic elements required for packaging, stable integration of the viral expression construct into genomic DNA, and expression of the effector or reporter. 2. The lentiviral packaging plasmids that provide the proteins essential for transcription and packaging of an RNA copy of the expression construct into recombinant pseudoviral particles. This protocol uses the pPACK plasmids (SBI) that encode for gag, pol, and rev from the HIV or FIV genome and Vesicular Stomatitis Virus g protein (VSV-G) for the viral coat protein. 3. 293TN producer cells (derived from HEK293 cells) that express the SV40 large T antigen, which is required for high-titer lentiviral production and a neomycin resistance gene, useful for reselecting the cells for maintenance. An overview of the viral production protocol can be seen in Figure 1. Viral production starts by co-transfecting 293TN producer cells with the lentiviral expression vector and the packaging plasmids. Viral particles are secreted into the media. After 48-72 hours the cell culture media is harvested. Cellular debris is removed from the cell culture media, and the viral particles are precipitated by centrifugation with PEG-it for concentration. Produced lentiviral particles are then titered and can be used to transduce target cells. Details of viral titering are not included in this protocol, but can be found at: http://www.systembio.com/downloads/global_titer_kit_web_090710.pdf. This protocol has been optimized using the specific products indicated. Other reagents may be substituted, but the same results cannot be guaranteed.
Similar articles
-
Production of lentiviral vectors for transducing cells from the central nervous system.J Vis Exp. 2012 May 24;(63):e4031. doi: 10.3791/4031. J Vis Exp. 2012. PMID: 22664962 Free PMC article.
-
Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.J Gene Med. 2005 Jun;7(6):818-34. doi: 10.1002/jgm.726. J Gene Med. 2005. PMID: 15693055
-
A new-generation stable inducible packaging cell line for lentiviral vectors.Hum Gene Ther. 2001 May 20;12(8):981-97. doi: 10.1089/104303401750195935. Hum Gene Ther. 2001. PMID: 11387062
-
Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.Curr HIV Res. 2004 Apr;2(2):185-91. doi: 10.2174/1570162043484906. Curr HIV Res. 2004. PMID: 15078182 Review.
-
Gene delivery by lentivirus vectors.Mol Biotechnol. 2007 Jul;36(3):184-204. doi: 10.1007/s12033-007-0010-8. Mol Biotechnol. 2007. PMID: 17873406 Review.
Cited by
-
Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019.Front Microbiol. 2022 Jan 14;12:817200. doi: 10.3389/fmicb.2021.817200. eCollection 2021. Front Microbiol. 2022. PMID: 35095820 Free PMC article. Review.
-
Development and validation of a droplet digital PCR method for quantifying lentiviral vector infectious titer.Heliyon. 2024 Oct 1;10(20):e38512. doi: 10.1016/j.heliyon.2024.e38512. eCollection 2024 Oct 30. Heliyon. 2024. PMID: 39498040 Free PMC article.
-
Epigenetic Regulation of Claudin-1 in the Development of Ovarian Cancer Recurrence and Drug Resistance.Front Oncol. 2021 Mar 22;11:620873. doi: 10.3389/fonc.2021.620873. eCollection 2021. Front Oncol. 2021. PMID: 33828978 Free PMC article.
-
A TALEN-based strategy for efficient bi-allelic miRNA ablation in human cells.RNA. 2014 Jun;20(6):948-55. doi: 10.1261/rna.042010.113. Epub 2014 Apr 9. RNA. 2014. PMID: 24717974 Free PMC article.
-
Viral Cre-LoxP tools aid genome engineering in mammalian cells.J Biol Eng. 2017 Nov 24;11:45. doi: 10.1186/s13036-017-0087-y. eCollection 2017. J Biol Eng. 2017. PMID: 29204184 Free PMC article.
References
-
- Cann AJ, editor. RNA Viruses. A Practical Approach. Oxford Univ. Press; 2000.
-
- Gould DJ, Favorov P. Vectors for the treatment of autoimmune diseases. Gene Therapy. 2003;10:912–927. - PubMed
-
- Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–267. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials